BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18245477)

  • 1. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis.
    Finetti P; Cervera N; Charafe-Jauffret E; Chabannon C; Charpin C; Chaffanet M; Jacquemier J; Viens P; Birnbaum D; Bertucci F
    Cancer Res; 2008 Feb; 68(3):767-76. PubMed ID: 18245477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gene expression signature identifies two prognostic subgroups of basal breast cancer.
    Sabatier R; Finetti P; Cervera N; Lambaudie E; Esterni B; Mamessier E; Tallet A; Chabannon C; Extra JM; Jacquemier J; Viens P; Birnbaum D; Bertucci F
    Breast Cancer Res Treat; 2011 Apr; 126(2):407-20. PubMed ID: 20490655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated profiling of basal and luminal breast cancers.
    Adélaïde J; Finetti P; Bekhouche I; Repellini L; Geneix J; Sircoulomb F; Charafe-Jauffret E; Cervera N; Desplans J; Parzy D; Schoenmakers E; Viens P; Jacquemier J; Birnbaum D; Bertucci F; Chaffanet M
    Cancer Res; 2007 Dec; 67(24):11565-75. PubMed ID: 18089785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling of breast cell lines identifies potential new basal markers.
    Charafe-Jauffret E; Ginestier C; Monville F; Finetti P; Adélaïde J; Cervera N; Fekairi S; Xerri L; Jacquemier J; Birnbaum D; Bertucci F
    Oncogene; 2006 Apr; 25(15):2273-84. PubMed ID: 16288205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.
    Bertucci F; Finetti P; Cervera N; Charafe-Jauffret E; Mamessier E; Adélaïde J; Debono S; Houvenaeghel G; Maraninchi D; Viens P; Charpin C; Jacquemier J; Birnbaum D
    Cancer Res; 2006 May; 66(9):4636-44. PubMed ID: 16651414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Histopathologic diagnosis of luminal and basal type breast cancer].
    Sarcević B
    Acta Med Croatica; 2008 Oct; 62(4):427-30. PubMed ID: 19205420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinome expression profiling and prognosis of basal breast cancers.
    Sabatier R; Finetti P; Mamessier E; Raynaud S; Cervera N; Lambaudie E; Jacquemier J; Viens P; Birnbaum D; Bertucci F
    Mol Cancer; 2011 Jul; 10():86. PubMed ID: 21777462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated gene expression profile predicts prognosis of breast cancer patients.
    Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
    Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
    Loi S; Haibe-Kains B; Desmedt C; Lallemand F; Tutt AM; Gillet C; Ellis P; Harris A; Bergh J; Foekens JA; Klijn JG; Larsimont D; Buyse M; Bontempi G; Delorenzi M; Piccart MJ; Sotiriou C
    J Clin Oncol; 2007 Apr; 25(10):1239-46. PubMed ID: 17401012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of 70-gene prognosis signature in node-negative breast cancer.
    Bueno-de-Mesquita JM; Linn SC; Keijzer R; Wesseling J; Nuyten DS; van Krimpen C; Meijers C; de Graaf PW; Bos MM; Hart AA; Rutgers EJ; Peterse JL; Halfwerk H; de Groot R; Pronk A; Floore AN; Glas AM; Van't Veer LJ; van de Vijver MJ
    Breast Cancer Res Treat; 2009 Oct; 117(3):483-95. PubMed ID: 18819002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [DNA microarrays for gene expression profiling of breast cancer: principles and prognostic applications].
    Bertucci F; Viens P; Birnbaum D
    Pathol Biol (Paris); 2006 Feb; 54(1):49-54. PubMed ID: 16376179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX.
    Kaklamani V
    Expert Rev Mol Diagn; 2006 Nov; 6(6):803-9. PubMed ID: 17140367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gene expression profiling of ER+ breast cancers: to discriminate the poor prognosis tumors or to define the most suitable treatment?].
    Chanrion M; Darbon JM
    Bull Cancer; 2008 May; 95(5):513-8. PubMed ID: 18541515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus genes of the literature to predict breast cancer recurrence.
    Lauss M; Kriegner A; Vierlinger K; Visne I; Yildiz A; Dilaveroglu E; Noehammer C
    Breast Cancer Res Treat; 2008 Jul; 110(2):235-44. PubMed ID: 17899371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic and predictive impact of protein expression profiling in high risk breast cancer patients treated with high-dose chemotherapy].
    Diallo-Danebrock R; Ting E; Gluz O; Herr A; Mohrmann S; Geddert H; Gabbert HE; Nitz U; Poremba C
    Verh Dtsch Ges Pathol; 2007; 91():187-96. PubMed ID: 18314614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
    Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
    Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
    Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
    BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
    Loi S
    Eur J Cancer; 2008 Dec; 44(18):2813-8. PubMed ID: 18990560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
    Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L
    Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.